Webinar for State Officials Only: Balancing Value and Affordability – Lessons from New York’s Medicaid Drug Cap and the Role of the Institute for Clinical and Economic Review
Tuesday, April 9, 2019
3:30 to 4:30 p.m. (EST)
In its first year of implementation, New York’s Medicaid Drug Cap received national attention for its unique approach to the rising cost of prescription drugs. The cap allows the New York Health Commissioner to negotiate a supplemental rebate with manufacturers if spending on a drug exceeds the cap. Entering its second year of implementation, what have state officials learned? How have assessments from the Institute for Clinical and Economic Review (ICER) informed New York’s process? Join NASHP for a state officials-only webinar to hear updates about New York’s Medicaid Drug Cap and learn more about ICER’s approach of bringing a focus on value to the current debate on high-priced prescription drugs. This webinar provides an opportunity for state officials to ask questions and explore more about what ICER is – and isn’t- and about how New York’s experience might inform other state action. This webinar is for state officials only, and will not be recorded.
The moderator is NASHP Executive Director Trish Riley.
Speakers are:
- Amir Bassiri, MA, Senior Policy Advisor for Health, Office of Governor Andrew M. Cuomo
- Steven D. Pearson, MD, MSc, Founder and President, Institute for Clinical and Economic Review (ICER)

For individuals living with complex, often chronic conditions, and their families, palliative care can provide relief from symptoms, improve satisfaction and outcomes, and help address critical mental and spiritual needs during difficult times. Now more than ever, there is growing recognition of the importance of palliative care services for individuals with serious illness, such as advance care planning, pain and symptom management, care coordination, and team-based, multi-disciplinary support. These services can help patients and families cope with the symptoms and stressors of disease, better anticipate and avoid crises, and reduce unnecessary and/or unwanted care. While this model is grounded in evidence that demonstrates improved quality of life, better outcomes, and reduced cost for patients, only a fraction of individuals who could benefit from palliative care receive it. 























































































































































